• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

    11/14/24 8:59:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EWTX alert in real time by email
    SC 13G/A 1 e664013_sc13ga-edgewise.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (Amendment No. 3)*

     

    Edgewise Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    28036F105

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed: 

             

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    (Page 1 of 11 Pages)

     

    _________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

              

     

    CUSIP No. 28036F105 13G Page 2 of 11

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Mgmt, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    479,380 (1)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    479,380 (1)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    479,380 (1)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.51%

    12.

    TYPE OF REPORTING PERSON*

     

    PN

     __________________

    (1) Comprised of shares of Common Stock held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner.

          

     

    CUSIP No. 28036F105 13G Page 3 of 11

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Mgmt IV, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    1,301,626 (2)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    1,301,626 (2)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,301,626 (2)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    1.39%

    12.

    TYPE OF REPORTING PERSON*

     

    PN

    _________________

    (2) Comprised of shares of common stock held by Deerfield Private Design Fund IV, L.P., of which Deerfield Mgmt IV, L.P. is the general partner.

      

      

    CUSIP No. 28036F105 13G Page 4 of 11

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Partners, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    479,380

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    479,380

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    479,380

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.51%

    12.

    TYPE OF REPORTING PERSON*

     

    PN 

         

       

    CUSIP No. 28036F105 13G Page 5 of 11

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Private Design Fund IV, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    1,301,626

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    1,301,626

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,301,626

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    1.39%

    12.

    TYPE OF REPORTING PERSON*

     

    PN 

         

       

    CUSIP No. 28036F105 13G Page 6 of 11

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Management Company, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    1,781,006 (3)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    1,781,006 (3)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,781,006 (3)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    1.90%

    12.

    TYPE OF REPORTING PERSON*

     

    PN 

    __________________

    (3) Comprised of shares of Common Stock held by Deerfield Partners, L.P. and Deerfield Private Design Fund IV L.P., of which Deerfield Management Company, L.P. is the investment advisor.

      

       

    CUSIP No. 28036F105 13G Page 7 of 11

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    James E. Flynn

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    1,781,006 (4)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    1,781,006 (4)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,781,006 (4)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    1.90%

    12.

    TYPE OF REPORTING PERSON*

     

    IN

    __________________

    (4) Comprised of shares of Common Stock held by Deerfield Partners, L.P. and Deerfield Private Design Fund IV L.P.

      

     

    CUSIP No. 28036F105 13G Page 8 of 11

     

    Item 1(a). Name of Issuer:
       
     

    Edgewise Therapeutics, Inc.

       
    Item 1(b). Address of Issuer's Principal Executive Offices:
       
     

    1715 38th St.,

    Boulder, Colorado 803013

       
    Item 2(a). Name of Person Filing:
       
     

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund IV, L.P.

       
    Item 2(b). Address of Principal Business Office, or if None, Residence:
       
     

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund IV, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010

       
    Item 2(c). Citizenship:
       
     

    Deerfield Mgmt, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund IV, L.P. - Delaware limited partnerships;

     

    James E. Flynn – United States citizen

       
    Item 2(d). Title of Class of Securities:
       
     

    Common Stock

       
    Item 2(e). CUSIP Number:
       
     

    28036F105

         
    Item 3.

    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

       
    (a) ☐

    Broker or dealer registered under Section 15 of the Exchange Act.

         
    (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act.
         
    (c) ☐

    Insurance company as defined in Section 3(a)(19) of the Exchange Act.

         
    (d) ☐

    Investment company registered under Section 8 of the Investment Company Act.

         
    (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f) ☐

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

         
    (g) ☐

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

         

    (h)

    ☐

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

         
    (i) ☐

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

      

     

    CUSIP No. 28036F105 13G Page 9 of 11

      

    (j) ☐ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
         
    (k) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________

     

    Item 4. Ownership.
           

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

           
    (a) Amount beneficially owned**:  
           
     

    Deerfield Mgmt, L.P. - 479,380 shares

    Deerfield Mgmt IV, L.P. – 1,301,626 shares

    Deerfield Management Company, L.P. - 1,781,006 shares

    Deerfield Partners, L.P. - 479,380 shares

    Deerfield Private Design Fund IV, L.P. – 1,301,626 shares

    James E. Flynn – 1,781,006 shares

           
    (b) Percent of class**:  
           
     

    Deerfield Mgmt, L.P. – 0.51%

    Deerfield Mgmt IV, L.P. – 1.39%

    Deerfield Management Company, L.P. – 1.90%

    Deerfield Partners, L.P. - 0.51%

    Deerfield Private Design Fund IV, L.P. – 1.39%

    James E. Flynn – 1.90% 

           
    (c) Number of shares as to which such person has**:  
           
      (i) Sole power to vote or to direct the vote: All Reporting Persons - 0
           
      (ii) Shared power to vote or to direct the vote:

    Deerfield Mgmt, L.P. - 479,380

    Deerfield Mgmt IV, L.P. – 1,301,626

    Deerfield Management Company, L.P. - 1,781,006

    Deerfield Partners, L.P. - 479,380

    Deerfield Private Design Fund IV, L.P. – 1,301,626

    James E. Flynn – 1,781,006

           
      (iii)

    Sole power to dispose or to direct the disposition of:

    All Reporting Persons - 0
           
      (iv)

    Shared power to dispose or to direct the disposition of:

    Deerfield Mgmt, L.P. - 479,380

    Deerfield Mgmt IV, L.P. – 1,301,626

    Deerfield Management Company, L.P. - 1,781,006

    Deerfield Partners, L.P. - 479,380

    Deerfield Private Design Fund IV, L.P. – 1,301,626

    James E. Flynn – 1,781,006

      

    **See footnotes on cover pages which are incorporated by reference herein.

      

     

    CUSIP No. 28036F105 13G Page 10 of 11

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

       

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following ☒.

       
       
       
    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

       

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

       
      N/A
       
    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. 

       

    If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

       
      N/A
       
    Item 8.

    Identification and Classification of Members of the Group. 

       

    If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group. 

       
      See Exhibit B
       
    Item 9. Notice of Dissolution of Group.
       

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

       
      N/A
       
    Item 10. Certifications.
       

    "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11

     

     

    CUSIP No. 28036F105 13G Page 11 of 11

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DEERFIELD MGMT, L.P.

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD MANAGEMENT COMPANY, L.P.

    By: Flynn Management LLC, General Partner

     

    By: /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD MGMT IV, L.P.

     

    By: J.E. Flynn Capital IV, LLC, General Partner

     

    By: /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD PARTNERS, L.P.

    By: Deerfield Mgmt, L.P., General Partner

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD PRIVATE DESIGN FUND IV, L.P.

    By: Deerfield Mgmt IV, L.P., General Partner

    By: J.E. Flynn Capital IV, LLC, General Partner

     

    By: /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    JAMES E. FLYNN

     

    /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    Date: November 14, 2024

     

     

     

     

    Exhibit List

     

    Exhibit A. Joint Filing Agreement.
       
    Exhibit B. Item 8 Statement.
       
    Exhibit C. Power of Attorney (1).

     

    (1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.

     

     

     

     

    Exhibit A

     

    Joint Filing Agreement

     

    The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Edgewise Therapeutics, Inc. shall be filed on behalf of the undersigned.

     

    DEERFIELD MGMT, L.P.

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD MANAGEMENT COMPANY, L.P.

    By: Flynn Management LLC, General Partner

     

    By: /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD MGMT IV, L.P.

     

    By: J.E. Flynn Capital IV, LLC, General Partner

     

    By: /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD PARTNERS, L.P.

    By: Deerfield Mgmt, L.P., General Partner

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD PRIVATE DESIGN FUND IV, L.P.

    By: Deerfield Mgmt IV, L.P., General Partner

    By: J.E. Flynn Capital IV, LLC, General Partner

     

    By: /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    JAMES E. FLYNN

     

    /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

     

     

     

    Exhibit B

     

    Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.

     

    Get the next $EWTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EWTX

    DatePrice TargetRatingAnalyst
    4/30/2025$41.00Buy
    Guggenheim
    4/2/2025$14.00Sector Outperform → Sector Perform
    Scotiabank
    3/7/2025$50.00Sector Outperform
    Scotiabank
    1/22/2025$30.00Hold
    Stifel
    11/22/2024$45.00Outperform
    Evercore ISI
    3/7/2024$48.00Overweight
    Piper Sandler
    5/1/2023Buy
    Truist
    8/25/2022$5.00Neutral → Sell
    Goldman
    More analyst ratings

    $EWTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – – Strengthened balance sheet with net proceeds of approximately $188 million from the April 2025 public offering; pro-forma cash balance exceeds $624 million – –  On track to report data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne muscular dystrophy (Duchenne) in the second quarter of 2025 – – Expect to report data from Part D of the Phase 2 CIRRUS-HCM trial in the second half of 2025 – BOULDER, Colo., May 8, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today reported financial results

      5/8/25 8:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock

      BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at an offering price of $20.13 per share. Edgewise anticipates gross proceeds from the offering to be approximately $200 million, before deducting underwriting discounts and commissions and offering expenses. The closing of the offering is expected to occur on April 3, 2025, subject to the satisfaction of customary closing conditions. The deal

      4/2/25 6:22:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)

      – Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM – – Four-week treatment with EDG-7500 demonstrated substantial improvements in measures of feel and function, reductions in key cardiac biomarkers and positive trends in measures of diastolic function – – EDG-7500 was generally well-tolerated; clinical activity was observed without meaningful changes in LVEF, including no participant with a value below 50% – BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line data of EDG-7500 from th

      4/2/25 6:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EWTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thompson Peter A. bought $10,000,000 worth of shares (496,771 units at $20.13) (SEC Form 4)

      4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

      4/4/25 7:42:30 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Orbimed Advisors Llc bought $10,000,000 worth of shares (496,771 units at $20.13) (SEC Form 4)

      4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

      4/4/25 7:33:31 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Thompson Peter A. bought $4,999,995 worth of shares (454,545 units at $11.00) (SEC Form 4)

      4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

      1/25/24 4:32:07 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EWTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Russell Alan J converted options into 5,209 shares and sold $25,520 worth of shares (1,551 units at $16.45), increasing direct ownership by 25% to 18,521 units (SEC Form 4)

      4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

      5/7/25 9:10:58 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Moore John R converted options into 5,209 shares and sold $31,757 worth of shares (1,930 units at $16.45), increasing direct ownership by 101% to 6,531 units (SEC Form 4)

      4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

      5/7/25 9:10:38 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Koch Kevin converted options into 10,417 shares and sold $70,358 worth of shares (4,276 units at $16.45), increasing direct ownership by 42% to 20,619 units (SEC Form 4)

      4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

      5/7/25 9:10:20 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EWTX
    Financials

    Live finance-specific insights

    See more
    • Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

      – Remarkable North Star Ambulatory Assessment scale (NSAA) improvements relative to BMD natural history trajectories – – Significant decrease in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers strongly associated with muscle damage caused by BMD – – EDG-5506 continues to be well-tolerated with no serious adverse events observed – – Management hosting webcast to discuss findings on September 12 at 8:30 a.m. Eastern Time – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today pos

      9/11/22 5:00:00 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

      – EDG-5506 treatment significantly lowered muscle damage biomarkers in adults with BMD – – BMD patients were more active during 2 months of dosing with EDG-5506 relative to activity measured in BMD patients in the Phase 1 study – – EDG-5506 was well tolerated with no serious adverse events observed; safety profile supported dose escalation to 15 mg daily for all patients – – Management hosting webcast to discuss findings on June 21 at 9:00 a.m. Eastern Time – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 2-month

      6/20/22 8:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference

      - Edgewise management to host webcast conference call on Tuesday, June 21, 2022 at 9 a.m. Eastern Time - - Additional presentations and posters featuring EDG-5506 to be featured at the New Directions Conference and the upcoming PPMD Annual Conference - Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that new 2-month interim data from the ARCH open label study of EDG-5506 in individuals with BMD will be presented at the 2022 New Directions in Biology and Disease of Skeletal Muscle Conference, being held June 20-23, 2022. Edgewise ARCH Interi

      6/16/22 8:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EWTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

      Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology industry veteran Arlene Morris to its Board of Directors. Ms. Morris has extensive experience in the pharmaceutical and biotechnology industries serving in numerous executive management and board roles. "With over 30 years of exceptional leadership experience in the biotech industry, we are delighted to welcome Arlene to our Board," said Kevin Koch, Ph.D., President and Chief Executive Officer. "Arlene brings invaluable expertise in strategic development and operational excellence, and we are thankful to count her as a valued advisor as we contin

      5/7/24 8:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors

      – President and Chief Medical Officer (CMO) of BridgeBio Pharma and Former CMO of MyoKardia brings strong cardiovascular expertise to Edgewise – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Jonathan C. Fox, M.D., Ph.D., FACC, to its Board of Directors. Dr. Fox brings considerable expertise in clinical development and regulatory strategy to Edgewise, serving currently as President and CMO at BridgeBio Pharma, and previously as CMO at MyoKardia, where he was one of the inventors of Camzyos

      3/6/23 8:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer

      – Former Chief Medical Officer of MyoKardia and Renovacor to lead cardiovascular development at Edgewise – Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Marc Semigran, M.D., as Chief Development Officer. Dr. Semigran brings considerable clinical development and translational medicine experience to Edgewise, having most recently served as Chief Medical Officer (CMO) at Renovacor through its acquisition by Rocket Pharmaceuticals, Inc., and previously served as CMO and Senior Vice President o

      12/20/22 9:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EWTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

      SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)

      11/14/24 6:22:11 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

      SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)

      11/14/24 4:31:39 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Edgewise Therapeutics Inc.

      SC 13G - Edgewise Therapeutics, Inc. (0001710072) (Subject)

      11/14/24 4:14:38 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EWTX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Edgewise Therapeutics Inc.

      10-Q - Edgewise Therapeutics, Inc. (0001710072) (Filer)

      5/8/25 8:05:22 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)

      5/8/25 8:00:45 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Edgewise Therapeutics Inc.

      DEFA14A - Edgewise Therapeutics, Inc. (0001710072) (Filer)

      4/29/25 4:16:25 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EWTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Edgewise Therapeutics with a new price target

      Guggenheim initiated coverage of Edgewise Therapeutics with a rating of Buy and set a new price target of $41.00

      4/30/25 8:12:14 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics downgraded by Scotiabank with a new price target

      Scotiabank downgraded Edgewise Therapeutics from Sector Outperform to Sector Perform and set a new price target of $14.00

      4/2/25 11:46:29 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Edgewise Therapeutics with a new price target

      Scotiabank initiated coverage of Edgewise Therapeutics with a rating of Sector Outperform and set a new price target of $50.00

      3/7/25 8:04:46 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care